

FUTURE PLANS AND USE OF [REDACTED]

FUTURE PLANS

See “Business — Our Growth Strategies” for a detailed description of our future plans.

USE OF [REDACTED]

We estimate that we will receive net [REDACTED] of approximately HK\$[REDACTED] from the [REDACTED], after deducting [REDACTED], [REDACTED] and other estimated expenses in connection with the [REDACTED] to be paid and payable by us, assuming that the [REDACTED] is not exercised and an [REDACTED] of HK\$[REDACTED] per H Share, being the mid-point of the indicative [REDACTED] of HK\$[REDACTED] to HK\$[REDACTED] per share.

In line with our strategies, we intend to use the net [REDACTED] for the following purposes:

- (a) **Core Product iNowill R&D and Registration.** iNowill is our core iNO therapy device for ICU and hospital bedside use. It has been approved in the Chinese mainland as a Class III medical device for the treatment of PH and has obtained CE certification as a Class IIb medical device for PH under the EU MDR. We plan to expand indications, complete clinical and regulatory work in the Chinese mainland, the European Union and the United States, and further enhance product performance of iNowill. Approximately [REDACTED]%, or HK\$[REDACTED], will be used for such purposes, of which:
 - (i) **Indication expansion in Chinese Mainland.** Approximately [REDACTED]%, or HK\$[REDACTED], of the net [REDACTED] will be used to fund ongoing and planned clinical trials of iNowill for indication-expansion in the PRC, including clinical trials in ARDS, CAP and COPD. The [REDACTED] will primarily be used to cover clinical trial-related expenses, including costs of recruiting and employing additional regulatory affairs and medical personnel, clinical trial site and investigator fees, patient recruitment and other patient-related costs, CRO/SMO service fees, as well as other related expenses such as travel and logistics costs. The remaining funding requirement will be financed by the Company’s operating cash flows and financing activities. Specifically:
 - Indication expansion for COPD: approximately [REDACTED]%, or HK\$[REDACTED], will be used to fund clinical trials for expanding indication of COPD in the PRC. The clinical trial is expected to be initiated in the second quarter of 2027 and completed by 2030, with an expected enrolment of approximately 500 patients. Of the allocated [REDACTED], (i) approximately HK\$[REDACTED] will be used for the recruitment and employment of additional regulatory affairs and medical personnel supporting the clinical program, and (ii) approximately HK\$[REDACTED] will be used for the conduct of the clinical trial, comprising approximately HK\$[REDACTED] in fees payable to participating clinical trial sites, HK\$[REDACTED] for patient recruitment and other patient-related costs, HK\$[REDACTED] in service fees payable to CROs and SMOs, and HK\$[REDACTED] for travel and meeting expenses, trial equipment and consumables and other trial-related expenses.
 - Indication expansion for ARDS: approximately [REDACTED]%, or HK\$[REDACTED] will be used to fund clinical trials for expanding indication of ARDS in the PRC. The clinical trial is expected to be initiated in 2026 and completed by 2029, with an expected enrolment of approximately 350 patients. Of the allocated [REDACTED], (i) approximately HK\$[REDACTED] will be used for the recruitment and employment of additional regulatory affairs and medical personnel supporting the clinical program, and (ii) approximately HK\$[REDACTED] will be used for the conduct of the clinical trial, comprising approximately HK\$[REDACTED] in fees payable to participating clinical trial sites, HK\$[REDACTED] for patient recruitment and other patient-related costs, HK\$[REDACTED] in service fees payable to CROs and SMOs, and HK\$[REDACTED] for travel and meeting expenses, trial equipment and consumables and other trial-related expenses.

FUTURE PLANS AND USE OF [REDACTED]

- Indication expansion for CAP: approximately [REDACTED]%, or HK\$[REDACTED], will be used to fund clinical trials for expanding indication of CAP in the PRC. The clinical trial is expected to be initiated in 2029 and completed by 2034, with an expected enrolment of approximately 500 patients. Of the allocated [REDACTED], (i) approximately HK\$[REDACTED] will be used for the recruitment and employment of additional regulatory affairs and medical personnel supporting the clinical program, and (ii) approximately HK\$[REDACTED] will be used for the conduct of the clinical trial, comprising approximately HK\$[REDACTED] in service fees payable to CROs and SMOs and HK\$[REDACTED] for travel and meeting expenses and trial equipment and consumables.
- (ii) **PMCF and indication expansion in European Union.** Approximately [REDACTED]%, or HK\$[REDACTED], will be used for planned PMCF and indication-expansion clinical trials in the European Union. The [REDACTED] will primarily be used to cover clinical trial costs, notified body review fees, CRO/SMO service fees, costs associated with technical documentation and quality management system compliance, clinical evaluation report preparation costs, as well as post-market surveillance and regulatory compliance costs. The remaining funding requirement will be financed by our operating cash flows and financing activities. Specifically:
- Prospective clinical trial under the PMCF plan: approximately [REDACTED]%, or HK\$[REDACTED], will be used to fund the prospective clinical trial under the PMCF plan. The trial is expected to be initiated in the third quarter of 2026 and completed by 2028, with an expected total enrolment of approximately 160 patients, including 50 patients in the first stage. Of the allocated [REDACTED], (i) approximately HK\$[REDACTED] will be used for the recruitment and employment of additional regulatory affairs and medical personnel supporting the PMCF clinical investigation, and (ii) approximately HK\$[REDACTED] will be used for the conduct of the PMCF clinical investigation, comprising approximately HK\$[REDACTED] in fees payable to participating clinical trial sites, HK\$[REDACTED] for patient recruitment and other patient-related costs, HK\$[REDACTED] in service fees payable to CROs, and HK\$[REDACTED] for travel and meeting expenses, trial equipment and consumables and other trial-related expenses.
 - Indication expansion for ARDS: approximately [REDACTED]%, or HK\$[REDACTED], will be used to fund clinical trials for expanding indication of ARDS in the European Union. The clinical trial is expected to be initiated in 2026 and completed by 2029, with an expected enrolment of approximately [100] patients. Of the allocated [REDACTED], (i) approximately HK\$[REDACTED] will be used for the recruitment and employment of additional regulatory affairs and medical personnel supporting the clinical program, (ii) approximately HK\$[REDACTED] will be used for regulatory and registration activities, comprising approximately HK\$[REDACTED] in fees payable to the notified body for regulatory review, HK\$[REDACTED] for the preparation of regulatory submission documents and HK\$[REDACTED] for post-market surveillance and regulatory compliance, and (iii) approximately HK\$[REDACTED] will be used for the conduct of the clinical trial, comprising approximately HK\$[REDACTED] in fees payable to participating clinical trial sites, HK\$[REDACTED] for patient recruitment and other patient-related costs, HK\$[REDACTED] in service fees payable to CROs, and HK\$[REDACTED] for travel and meeting expenses, trial equipment and consumables and other trial-related expenses.

FUTURE PLANS AND USE OF [REDACTED]

- (iii) **Registration and indication expansion in the United States.** Approximately [REDACTED]%, or HK\$[REDACTED], will be used for clinical validation and registration of iNOwill for indications including PH and ARDS in the United States. The [REDACTED] will primarily be used to cover clinical trial costs, FDA regulatory fees, third-party testing and quality system-related costs, as well as other related expenses. The remaining funding requirement will be financed by our operating cash flows and financing activities. Specifically:
- Registration for PH: approximately [REDACTED]%, or HK\$[REDACTED], will be used to fund clinical trials for registration of PH in the United States. The clinical trial is expected to be initiated in 2028 and completed by 2032, with an expected enrolment of approximately 200 patients. Of the allocated [REDACTED], (i) approximately HK\$[REDACTED] will be used for the recruitment and employment of additional regulatory affairs and medical personnel supporting the clinical program, and (ii) approximately HK\$[REDACTED] will be used for the conduct of the clinical trial, comprising approximately HK\$[REDACTED] in fees payable to participating clinical trial sites, HK\$[REDACTED] for patient recruitment and other patient-related costs, HK\$[REDACTED] in service fees payable to CROs, and HK\$[REDACTED] for travel and meeting expenses and trial equipment and consumables.
 - Registration for ARDS: approximately [REDACTED]%, or HK\$[REDACTED], will be used to fund clinical trials for expanding indication of ARDS in the United States. The clinical trial is expected to be initiated in 2028 and completed by 2032, with an expected enrolment of approximately 300 patients. Of the allocated [REDACTED], (i) approximately HK\$[REDACTED] will be used for the recruitment and employment of additional regulatory affairs and medical personnel supporting the registration program, and (ii) approximately HK\$[REDACTED] will be used for regulatory submission activities, comprising approximately HK\$[REDACTED] for FDA application and review fees and HK\$[REDACTED] for the preparation of regulatory submission documents.
- (iv) Approximately [REDACTED]%, or HK\$[REDACTED], will be used for iterative upgrades of iNOwill, including engineering and system optimization to enhance continuous gas supply, upgrades to information systems and development of intelligent decision-support features, primarily covering software development and testing costs.

For details of our development plan for iNOwill, see “Business — iNO Therapy — iNOwill — Our Core Product — Further Development Plan.”

- (b) ***R&D and Registration of Other Pipeline Products and Product Candidates.*** Approximately [REDACTED]%, or HK\$[REDACTED], will be used for the development and registration of our other products and product candidates targeting different care settings, of which:
- (i) Approximately [REDACTED]%, or HK\$[REDACTED], will be used for the R&D, clinical trials and registration in the Chinese mainland of VQfit, our iNO therapy product candidate for outpatient and at-home use.

FUTURE PLANS AND USE OF [REDACTED]

- (ii) Approximately [REDACTED]%, or HK\$[REDACTED], will be used for the R&D, clinical trials and registration in the Chinese mainland of PELink and PSLink, our respiratory diagnostics product candidates for outpatient and at-home monitoring of chronic airway inflammatory diseases, and for the development of their intelligent data-diagnostic platform, including cloud-based data services and AI-enabled analysis to support outpatient and home management of respiratory diseases.
- (iii) Approximately [REDACTED]%, or HK\$[REDACTED], will be used for the R&D and registration in the Chinese mainland of NovaVent, our ventilator product candidate that integrates iNO therapy and electrical impedance tomography monitoring for ICU and perioperative use.
- (iv) Approximately [REDACTED]%, or HK\$[REDACTED], will be used for the clinical validation and registration in the European Union of eNOaire, our iNO therapy device based on electrical-arc technology for hospital and transfer scenarios.

For further details of these products and product candidates, see “Business — Our Product Pipeline.”

- (c) ***Domestic and Overseas Commercialization.*** We plan to strengthen our commercialization capabilities in the Chinese mainland and overseas by expanding our distribution network, building dedicated sales and marketing teams and rolling out digital customer-management and service systems to support the launch and scaling of iNOWill and our other products. Approximately [REDACTED]%, or HK\$[REDACTED], will be used for this purpose. Specifically, we expect that approximately [REDACTED]%, or HK\$[REDACTED] will be allocated to our Core Product and approximately [REDACTED]%, or HK\$[REDACTED] will be allocated to our other product candidates. As iNOWill is based on a relatively new instant nitric oxide generation technology, its commercialization requires continued investment in market development, clinical education and distributor support to facilitate product adoption. In addition, we are actively pursuing overseas market opportunities and plan to further expand our overseas distributor network and sales and marketing capabilities to support our international growth strategy, with HK\$[REDACTED] allocated for overseas development. Among the [REDACTED] of HK\$[REDACTED]:

- (i) Approximately [REDACTED]%, or HK\$[REDACTED], will be used for the development of our distributor network and sales-support systems, including:
 - approximately [REDACTED]%, or HK\$[REDACTED] will be used for the recruitment and onboarding of domestic and overseas distributors among which approximately [REDACTED]%, or HK\$[REDACTED], will be used for recruitment of overseas distributors,
 - approximately [REDACTED]%, or HK\$[REDACTED] will be used for the establishment of a global distributor training and support system, and
 - approximately [REDACTED]%, or HK\$[REDACTED] will be used for the implementation and upgrade of our customer-management and global customer-service systems.
- (ii) Approximately [REDACTED]%, or HK\$[REDACTED], will be used for sales and marketing personnel recruitment and their on-board training. We expect that approximately [REDACTED]%, or HK\$[REDACTED], will be allocated to recruitment of personnel focused on overseas sales and marketing activities.

FUTURE PLANS AND USE OF [REDACTED]

(iii) Approximately [REDACTED]%, or HK\$[REDACTED], will be used for marketing in the Chinese mainland and overseas, including:

- approximately [REDACTED]%, or HK\$[REDACTED] will be used for the participation in high-level overseas academic conferences for iNOwill,
- approximately [REDACTED]%, or HK\$[REDACTED] will be used for the overseas expert consultancy fees and
- approximately [REDACTED]%, or HK\$[REDACTED] will be used for the training and preceptorship programs for KOL physicians.

For details of our commercialization strategies, see “Business — Our Commercialization Strategies.”

(d) ***R&D Infrastructure and Production Line Automation.*** We plan to upgrade our R&D infrastructure and product line automation to support continuous innovation and enhance our capability to manufacture high-quality products at scale. Approximately [REDACTED]%, or HK\$[REDACTED], will be used for this purpose, of which:

(i) Approximately [REDACTED]%, or HK\$[REDACTED], will be used for general R&D infrastructure and system upgrades across our product portfolio, including laboratory equipment, computer-aided design and manufacturing tools, processing, assembly and packaging equipment, and digital quality-management tools such as manufacturing execution systems and electronic batch-recording systems.

(ii) Approximately [REDACTED]%, or HK\$[REDACTED], will be used to upgrade dedicated R&D infrastructure and automated production lines specific to iNOwill including sterilization, quality-testing and precision processing equipment, in order to improve development efficiency, product consistency and manufacturing scalability. We plan to upgrade the product line for iNO therapy devices (iNOwill/eNOaire), which utilization rate were 67.6% and 69.3% in 2024 and 2025, respectively. The upgrade focuses on self-developing more key components. In this way, we expect to develop customized components that better fit into our products, thereby reducing reliance on third-party suppliers, reducing production cost, and improving product yield rate. We plan to manufacture in-house the main unit of our iNO therapy devices. We had a production capacity of 692 units per year for iNOwill in 2025. Upon the completion of the planned production line upgrade, we expect to achieve an annual target production capacity of 2,363 units by 2028, representing an approximately 3.4 times increase. Upon reaching the target production capacity, we expect to reduce the production cost of each main unit by approximately RMB12,000, reflecting improved manufacturing efficiency and economies of scale.

(iii) Approximately [REDACTED]%, or HK\$[REDACTED], will be used to recruit production management personnel.

(e) ***Working Capital, Business Development and General Corporate Purpose.*** Approximately [REDACTED]%, or HK\$[REDACTED], will be used for working capital, business development and general corporate purposes, providing financial flexibility to support day-to-day operations and advance our pipeline. These funds will enable us to forge strategic partnerships that accelerate development, expand market reach, and mitigate risk.

FUTURE PLANS AND USE OF [REDACTED]

The table below summarizes the planned yearly allocation of the net [REDACTED] from the [REDACTED] by nature, from 2027 through 2030.

Yearly Allocation Summary	2027	2028	2029	2030	Total
	(HK\$ in [REDACTED])				
(a) Core Product iNowill R&D and Registration	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(i) Indication expansion in Chinese					
Mainland	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Indication expansion for COPD	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Indication expansion for ARDS	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Indication expansion for CAP	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(ii) PMCF and indication expansion in					
European Union	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
PMCF for PH	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Indication expansion for ARDS	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(iii) Registration and indication					
expansion in the United States	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Registration for PH	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Indication expansion for ARDS	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(iv) Iterative upgrades of iNowill	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(b) R&D and Registration of Other Pipeline Products and Product Candidates	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(c) Domestic and Overseas Commercialization	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(i) Distributor network and sales-support systems	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(ii) Sales and marketing personnel recruitment	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(iii) Marketing in the Chinese mainland and overseas	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(d) R&D Infrastructure and Production Line Automation	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
(e) Working Capital, Business Development and General Corporate Purpose	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Total	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Note: The exchange rate used for conversion is US\$1.00 = HK\$7.8449.

We believe our strategy of concurrently advancing multiple clinical programs is well-supported by clear commercial rationale, shared medical and scientific foundations across our target indications, and sufficient financial and organizational resources.

Commercial rationale. Our currently approved indication for iNowill, PH remains the established clinical and commercial anchor of the iNO therapy market, with approximately 84.0 million prevalent cases and an estimated PH-related iNO market of approximately US\$1.05 billion in 2025 (expected to reach approximately US\$1.52 billion by 2030 and US\$1.93 billion by 2035, representing CAGRs of approximately 7.5% and 4.9%, respectively). Although PH is expected to remain the largest indication, its growth is comparatively moderate. ARDS and COPD represent substantial incremental opportunities, with approximately 4.2 million new ARDS cases and 262.2 million prevalent COPD cases in 2025. Assuming successful regulatory approval and subsequent market adoption, their respective iNO markets are expected to reach approximately US\$54.6 million and US\$9.3 million by 2030, and approximately US\$678.0 million and US\$105.4 million by 2035, representing CAGRs of approximately 65.5% and 62.4% from 2030 to 2035, respectively. Together, the established PH market and the expansion potential of ARDS and COPD support the

FUTURE PLANS AND USE OF [REDACTED]

commercial rationale for advancing multiple iNO indications in parallel. Although the underlying ARDS case pool is smaller than the COPD prevalence pool, the two populations are not directly comparable, as ARDS is measured by annual new cases while COPD is measured by prevalent cases. Subject to regulatory approval, iNO may be used as rescue or bridging therapy in selected patients with severe or refractory ARDS in intensive care settings, whereas its potential use in COPD is expected to remain limited to a smaller subset of patients with severe exacerbations, hypoxemia and associated pulmonary hypertension or right ventricular dysfunction. The model therefore assumes higher clinical eligibility, market penetration and treatment intensity for ARDS than for COPD. The difference in projected market size reflects expected clinical applicability and utilization rather than the size of the underlying disease population. Advancing clinical programs across these indications in parallel, rather than sequentially, enables us to expand our addressable market more rapidly. In addition, our target indications, namely PH, ARDS and COPD, share significant commercial synergies, as patients with these conditions are typically managed within the same hospital departments (such as ICU, respiratory and cardiology departments). Therefore, the hospitals may be covered by same groups of distributors, allowing us to leverage existing distributor network.

Medical and scientific feasibility. According to Frost & Sullivan, PH, ARDS and COPD share certain overlapping pathophysiological features, such as hypoxemia, ventilation-perfusion mismatch and pulmonary vasoconstriction. In addition, the therapeutic mechanism across COPD and ARDS, such as nitric oxide-mediated pulmonary vasodilation, is fundamentally the same, and has already been clinically validated through PH indication. This shared therapeutic mechanism allows us to apply and leverage clinical insights, trial design experience and operational know-how gained from one program to the others, enhancing execution efficiency and reducing development risk.

Funding sufficiency and phased execution. We have allocated approximately [REDACTED]% of our net [REDACTED] from the [REDACTED], or approximately HK\$[REDACTED], to the R&D and registration of iNO will. The remaining funding requirements will be financed by our operating cash flows and financing activities. Pursuant to our current clinical trial plan, the majority of our clinical trials is expected to enter peak enrollment phases in 2028 and beyond. As our business continues to grow, we expect to have increased operating cash flows available in supporting our clinical programs during those peak periods.

The above allocation of the net [REDACTED] from the [REDACTED] will be adjusted on a pro rata basis in the event that the [REDACTED] is fixed at a higher or lower level compared to the mid-point of the indicative [REDACTED] stated in this document. If the [REDACTED] is fixed at the high-end or low-end of the [REDACTED], the net [REDACTED] will increase or decrease by approximately HK\$[REDACTED]. We intend to apply the additional or reduced net [REDACTED] to the above uses on a pro rata basis.

If the [REDACTED] is fully exercised, we will receive additional net [REDACTED] of approximately HK\$[REDACTED] from the allotment and issue of [REDACTED] Shares, based on an [REDACTED] of HK\$[REDACTED] per Share (the mid-point of the indicative [REDACTED]) and after deducting the [REDACTED] fees and [REDACTED] payable by our Company. We intend to apply such additional net [REDACTED] to the uses described above on a pro rata basis.

To the extent that the net [REDACTED] from the [REDACTED] are not immediately required for the above purposes and to the extent permitted by the relevant law and regulations, we will only place the net [REDACTED] from the [REDACTED] in short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions as defined under the Securities and Futures Ordinance or applicable laws and regulations in other jurisdictions.

We will make an appropriate announcement if there is any change to the above proposed use of [REDACTED].